期刊
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 3, 期 1, 页码 107-118出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.9b00087
关键词
trichosanthin; gelonin; ribosome-inactivating protein; tumor-targeting drug delivery; cell-penetrating peptide
资金
- NFSC [81925035, 81673382, 81521005]
- Strategic Priority Research Program of CAS [XDA12050307]
- National Special Project for Significant New Drugs Development [2018ZX09711002-010-002]
- Shanghai Sci-Tech innovation Action Plan [19431903100]
- Fudan-SIMM Joint Research Fund [FU-SIMM20174009]
- Uzbek Academy of Sciences [TA-FA-F6-002]
- CAS PIFI Fellowship [2019PB0076]
- Belt & Road Young Scientist Award (Shanghai) [18430740800]
Great attention has been paid to cytotoxic proteins (e.g., ribosome-inactivating proteins, RIPs) possessing high anticancer activities; unlike small drugs, cytotoxic proteins can effectively retain inside the cells and avoid drug efflux mediated by multidrug resistance transporters due to the large-size effect. However, the clinical translation of these proteins is severely limited because of various biobarriers that hamper their effective delivery to tumor cells. Hence, in order to overcome these barriers, many smart drug delivery systems (DDS) have been developed. In this review, we will introduce two representative type I RIPs, trichosanthin (TCS) and gelonin (Gel), and overview the major biobarriers for protein-based cancer therapy. Finally, we outline advances on the development of smart DDS for effective delivery of these cytotoxic proteins for various applications in cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据